CDK14 and synucleinopathy: Given the lack of phenotypes in the Cdk14−/− or Cdk14+/− mice, no evidence for loss of function intolerance in humans (probability of loss of function intolerance [pLI] = 0; gnomAD database, CDK14 | gnomAD v2.1.1) [54],) and the availability of a recently developed highly selective CDK14 inhibitor, we further explored the pharmacological tractability of CDK14 in the context of synucleinopathy.